Ara-290 vs BPC-157
Ara-290 (Synthetic erythropoietin-derived peptide (Cibinetide)) and BPC-157 (Synthetic pentadecapeptide) are documented as co-studied in the PeptiDex library. This page puts the two entries side by side on class, molecular weight, half-life, origin, mechanism and studied research areas — every value taken from the entry it belongs to.
Why these two are co-studied
Cross-referenced for research context — not a usage or combination recommendation.
At a glance
| Attribute | Ara-290 | BPC-157 |
|---|---|---|
| Compound class | Synthetic erythropoietin-derived peptide (Cibinetide) | Synthetic pentadecapeptide |
| Research category | Healing & Recovery | Healing & Recovery |
| Length (amino acids) | 11 amino acids | 15 amino acids |
| Molecular weight | ~1257 Da | 1419.5 Da |
| Half-life | ~2 minutes (plasma) | <30 minutes (elimination, reported in rats/dogs) |
| Origin | ARA-290, also known as Cibinetide, is a synthetic 11-amino-acid peptide derived from a region of the erythropoietin (EPO) molecule. It was designed to engage tissue-protective signaling associated with EPO while lacking EPO's erythropoietic (red-blood-cell-stimulating) activity. | BPC-157 is a synthetic peptide whose sequence corresponds to a partial fragment of human body protection compound (BPC), a protein reported to be present in gastric juice. It does not occur naturally as an isolated peptide and is produced synthetically for research. |
“Not documented” means the PeptiDex entry records no value for that field. Nothing on this page is estimated, and no figure is carried over from one compound to the other.
How Ara-290 works
ARA-290 is described as an agonist of the innate repair receptor, a heteroreceptor complex involving the beta-common receptor, which mediates tissue-protective and anti-inflammatory effects attributed to EPO without stimulating erythropoiesis. Through this pathway it has been studied for effects on inflammation and neuropathic processes. Mechanistic understanding derives from preclinical models and early clinical research.
How BPC-157 works
In animal and in-vitro studies, BPC-157 has been associated with promotion of angiogenesis and modulation of growth-factor signaling pathways, including effects reported on the VEGFR2 pathway and nitric oxide systems. Researchers have also described interactions with the FAK-paxillin pathway and effects on fibroblast and tendon-cell migration. These mechanisms are characterized primarily in rodent models and cell culture and have not been established in controlled human trials.
Mechanistic descriptions reflect published research-literature understanding and are quoted from each compound's own entry. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
Where each one appears in the literature
The research contexts each entry documents. Listing a research area is not a claim of efficacy or a therapeutic indication, and the two lists are not scored against each other.
Ara-290
BPC-157
What sets each apart
Ara-290
ARA-290 is unusual in this group for being an EPO-derived, receptor-targeted peptide that has progressed into clinical trials rather than remaining purely preclinical.
BPC-157
Unlike copper-binding cosmetic tripeptides or the actin-modulating TB-500, BPC-157 is a longer synthetic peptide studied primarily for connective-tissue and gastrointestinal repair endpoints in animals.
Frequently asked questions
What is ARA-290 (cibinetide)?
ARA-290, generic name cibinetide, is a synthetic 11-amino-acid linear peptide engineered from the helix-B surface region of erythropoietin (EPO). It was designed to selectively activate the innate repair receptor (a heterodimer of the EPO receptor and the beta-common receptor/CD131) without stimulating red-blood-cell production. It is an investigational compound, not an approved drug.
What is ARA-290 studied for?
It has been investigated in clinical research for tissue protection and anti-inflammatory effects, notably in sarcoidosis-associated small-fiber neuropathy and diabetic neuropathic pain, as well as organ-protection models. The rationale is that innate-repair-receptor activation drives tissue-protective and anti-inflammatory signaling. Results are from early-phase research rather than approved indications.
Does ARA-290 raise red blood cell counts like EPO?
No. It was specifically engineered to activate the tissue-protective innate repair receptor while not engaging the classical EPO receptor homodimer that drives erythropoiesis. In principle this avoids the thrombotic and cardiovascular risks associated with erythropoiesis-stimulating agents, though it is still investigational.
What is BPC-157 and what class of peptide is it?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide of 15 amino acids derived from a partial sequence of a protein found in human gastric juice. It is studied in the research literature as a cytoprotective and tissue-repair agent, not as an approved drug. It has no established endogenous receptor and its mechanisms are still under active investigation.
What is BPC-157 studied for in the research literature?
In animal models, BPC-157 has been researched in the context of tendon, ligament, muscle, and bone healing, gastrointestinal mucosal protection, and angiogenesis. Much of the work implicates nitric oxide pathways and upregulation of growth-factor and angiogenic signaling. To date these findings are almost entirely preclinical, and no human clinical efficacy has been established.
Why is BPC-157's short half-life not reflected in dosing frequency?
Pharmacokinetic work in rats and dogs reports an elimination half-life under about 30 minutes, yet most rodent studies use once-daily dosing. This is often described as a PK/PD disconnect: the downstream biological effects the peptide triggers persist well beyond the peptide's own residence time. Researchers therefore design protocols around effect duration rather than plasma half-life.
Answers are the ones published on each compound's own PeptiDex entry. They are educational summaries of research-literature context and are not medical advice.